Related Experiment Videos
Hyperprolactinaemia in males: a heterogeneous disorder
1Prince Henry's Institute of Medical Research, Melbourne, Vic.
Australian and New Zealand Journal of Medicine
|August 1, 1997
Summary
Hyperprolactinaemia in men often presents with hypogonadism or tumor effects. Treatment with bromocriptine improves symptoms and reduces prolactin-secreting macroadenoma size.
Area of Science:
- Endocrinology
- Oncology
Background:
- Male hyperprolactinaemia is often associated with pituitary tumors and hypogonadism.
- A comprehensive understanding of its clinical presentation in men is lacking.
Purpose of the Study:
- To define the clinical, biochemical, and radiological characteristics of hyperprolactinaemia in males.
- To evaluate treatment outcomes for male hyperprolactinaemia.
Main Methods:
- Retrospective analysis of 53 adult males with prolactinoma or idiopathic hyperprolactinaemia (1980-1995).
- Review of clinical symptoms, physical examinations, hormonal assays, and pituitary imaging (CT/MRI).
Main Results:
- Most common presenting symptoms were endocrine (57%), including loss of libido/potency (47%).
- Pituitary macroadenomas were found in 70% of patients.
- Bromocriptine treatment improved sexual function in 89% and reduced tumor size in 89% of cases.
Conclusions:
- Male hyperprolactinaemia is a diverse condition with varied presentations.
- Prolactin-secreting macroadenomas are common, but symptoms and findings differ widely.
- Bromocriptine therapy is effective for symptom relief and tumor shrinkage.